Reltecimod sodium
| Code | Size | Price |
|---|
| TAR-T26367L-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Reltecimod, a CD28 antigen inhibitor, is used potentially for the treatment of necrotizing soft tissue infection.
CAS:
1943755-99-4
Formula:
C46H71N10NaO15S
Molecular Weight:
1059.18
Purity:
0.98
SMILES:
[Na+].CSCCC(NC(=O)C1CCCN1C(=O)C(CO)NC(=O)C(C)N)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CC([O-])=O)C(=O)NC(C)C(O)=O
References
1. Ahn M, Han YH, Park JE, Kim S, Lee WC, Lee SJ, Gunasekaran P, Cheong C, Shin SY Sr, Kim HY, Ryu EK, Murugan RN, Kim NH, Bang JK. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1. J Med Chem. 2015 Jan 8;58(1):294-304. doi: 10.1021/jm501147g. Epub 2014 Nov 5. PubMed PMID: 25347203.
2. LIDDLE HV, THOMAS JM. AB-103 (NSC-37096) IN THE TREATMENT OF BRONCHOGENIC CARCINOMA. Cancer Chemother Rep. 1964 Jul;39:61-5. PubMed PMID: 14201277.
3. MECHL Z, KOLAR V, KONECNY M. THE USE OF THE DRUGS AB 103 AND AB 132 IN THE COMBINED TREATMENT OF TUMOURS OF THE CERVICAL AND PULMONARY REGIONS. Neoplasma. 1964;11:491-8. PubMed PMID: 14220338.
4. NEVINNY-STICKEL HB, DEDERICK MM, HAINES CR, HALL TC. A STUDY OF BENZCARBIMINE (AB-103; NSC-37096) IN PATIENTS WITH VARIOUS MALIGNANCIES. Cancer Chemother Rep. 1963 Dec;33:15-20. PubMed PMID: 14102077.